Building the next generation of gene therapy from anelloviruses - the harmless viruses that already live inside nearly every human body.
Gene therapy has a quiet, stubborn flaw. Most treatments are engineered from adeno-associated viruses, or AAV, and the immune system learns to recognize them fast. Give a patient one dose and their body builds antibodies that block the second. For a field promising to rewrite biology, "you only get one shot" is a serious limit.
Ring Therapeutics started from a different question: what if the delivery vehicle were a virus the body has already decided to tolerate? That virus exists. Anelloviruses are the most abundant and diverse members of the human commensal virome. They live in the blood of nearly every person on Earth, cause no known disease, and the immune system leaves them alone.
Founded by Flagship Pioneering - the same venture-creation engine behind Moderna - Ring set out to turn that biology into a platform. Since 2017 it has mined the human virome, built vectors from these viruses, and worked to solve gene therapy's three hardest problems at once: re-dosing, tissue targeting, and affordable manufacturing.
The name "Ring" is a scientist's inside joke: anelloviruses carry a ring-shaped, circular single-stranded DNA genome. The company is, quite literally, named after the shape of the thing it studies.
Because anelloviruses are tolerated by the immune system, Ring's AnelloVectors are designed to be re-administered - unlike conventional AAV therapies, which pre-existing immunity typically limits to a single dose.
The vectors are built from viruses the body already lives with, so they aim to slip past immune surveillance rather than provoke it - potentially widening the pool of patients who can be treated.
The diversity of the anellovirus family gives Ring many different "keys." Its Anellogy platform screens them for vectors that home to specific tissues - one of the hardest problems in gene delivery.
Viral vectors are famously expensive to produce. Ring's AnelloBricks in-vitro assembly technology is designed to manufacture vectors at scale and at dramatically lower cost.
The Anellogy engine sequences thousands of anelloviruses from human tissue samples.
Candidates are designed into AnelloVectors carrying a therapeutic payload.
AnelloBricks assembles vectors in vitro, at scale, with expanded payload versatility.
Vectors target specific tissues and are designed to be re-dosed over time.
Preclinical results reported by Ring include durable expression for nine months after subretinal (eye) administration in mice, and expression comparable to dose-matched AAV9 when delivered by the intracerebroventricular route. These are early-stage laboratory findings, not clinical outcomes.
Ring's discovery and engineering engine that mines the commensal virome to identify and design vector candidates with tissue-specific tropism and re-dosing potential.
Gene delivery vectors engineered from human anelloviruses, designed to evade pre-existing immunity, target specific tissues, and be re-administered.
In-vitro assembly technology that produces AnelloVectors at scale, with expanded payload versatility beyond the natural single-stranded DNA genome and dramatically lower cost.
Self-Amplifying Trans-complementation of a Universal Recombinant aNellovector - packages a payload into capsids drawn from multiple anelloviruses. Published in bioRxiv, 2024.
Bars are scaled to round size for illustration. Figures compiled from company press releases and public reporting.
Ring is a platform company. It does not yet sell a product. Its value lives in the technology - a proprietary way of building, targeting, and manufacturing gene therapy vectors - and in the pipeline of AnelloVector drug candidates that technology could produce.
The business is B2B in character: funded by venture and strategic investors, with future returns expected from its own therapeutic programs, partnerships, and potential licensing of the delivery platform to other developers. Strategic backers such as Kyowa Kirin and UPMC Enterprises signal interest from established players in the space.
Where does Ring sit in the market? Gene therapy delivery is a crowded, high-stakes race. Most of the field iterates on AAV; others - like Dyno Therapeutics with AI-designed capsids, or companies working on lentivirus and engineered vectors - chase the same goals of re-dosing and precision. Ring's wager is that starting from an entirely different, immune-tolerated virus family is a more durable edge than optimizing the vectors everyone else already uses.
Like most preclinical biotech, the path is long. Ring has navigated a restructuring and a leadership change in 2024-2025, yet continued to publish new data through the turbulence.
Founding CEO and Flagship Pioneering Partner who led a team of entrepreneurial scientists to discover thousands of anelloviruses and uncover their biology.
Founding Head of Innovation and Flagship Senior Associate, central to Ring's early virome discovery work.
Founder and CEO of Flagship Pioneering; co-founder and chairman of Ring Therapeutics.
Joined as CFO and Head of Corporate Strategy in 2023; assumed Interim CEO in early 2025 amid the company's restructuring.
Flagship Labs incubates the company around commensal virome biology.
Flagship unveils Ring Therapeutics in December with an initial $50 million capital commitment, led by founding CEO Avak Kahvejian.
Ring raises Series B to expand its novel vector platform, backed by Invus, T. Rowe Price, UPMC Enterprises and others.
Series C funds next-generation programmable medicines, adding strategic investors including Kyowa Kirin.
Ring publishes the SATURN system in bioRxiv - the first gene delivery vector built on a human anellovirus - with durable preclinical data.
CFO Chris McNulty becomes Interim CEO; Ring presents scalable, lower-cost AnelloBricks manufacturing data at ASGCT.
Ring develops gene therapy delivery vectors from anelloviruses - harmless viruses that naturally live in the human body - aiming to create re-dosable, tissue-specific, affordably manufactured genetic medicines.
Anelloviruses are the most abundant and diverse family of viruses in the human commensal virome. They are found in nearly everyone, cause no known disease, and are tolerated by the immune system - which is why Ring uses them as delivery vehicles.
Ring was founded by Flagship Pioneering, with founding CEO Avak Kahvejian, founding head of innovation Erica Weinstein, and co-founder/chairman Noubar Afeyan. It has raised over $253 million across its founding commitment, Series B, and Series C rounds.
Most gene therapies use AAV vectors that trigger an immune response, so patients typically cannot receive a second dose. Ring's anellovirus vectors are designed to evade pre-existing immunity, potentially allowing therapies to be given more than once.
No. As of 2025, Ring is a preclinical-stage platform company. It has published preclinical data on its AnelloVector and AnelloBricks technologies but does not yet have a marketed product.
Video: search "Ring Therapeutics anellovirus" or "Flagship Pioneering Ring" on YouTube for platform explainers and conference presentations. No official product-demo video URL is publicly confirmed at time of writing.